FDA approves Roche's Gazyva (obinutuzumab) for people with previously untreated chronic lymphocytic leukemia (CLL)

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL). Gazyva is the first medicine approved with the FDA's Breakthrough Therapy Designation and the fifth cancer medicine from Roche approved by the FDA in the past three years...